ES
IMNM icon

Enavate Sciences’s Immunome IMNM Stock Holding History

Enavate Sciences’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.6M Hold
3,613,799
– – 22.17% 3
2026
Q1 		$79M Sell
3,613,799
-1,154,784
-24% -$25.7M 22.48% 2
2025
Q4 		$102M Hold
4,768,583
– – 20.21% 2
2025
Q3 		$55.8M Hold
4,768,583
– – 17.05% 3
2025
Q2 		$44.3M Hold
4,768,583
– – 25.12% 1
2025
Q1 		$32.1M Buy
4,768,583
+1,290,322
+37% +$12.4M 24.18% 1
2024
Q4 		$36.9M Buy
+3,478,261
New +$42M 26.53% 2

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Enavate Sciences's IMNM Position: Q2 2026 in Review

Enavate Sciences held its Immunome (IMNM) position steady in Q2 2026 at 3,613,799 shares worth $76.6M. The position accounts for 22.17% of the portfolio, ranked #3.

Enavate Sciences first reported a position in IMNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $102M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Enavate Sciences held 3,613,799 shares of Immunome worth $76.6M as of Q2 2026.
  • Enavate Sciences left its Immunome share count unchanged in Q2 2026.
  • Immunome made up 22.17% of Enavate Sciences's portfolio in Q2 2026, its #3 holding.
  • Enavate Sciences first reported a position in Immunome in Q4 2024 and has held it in 7 quarters since.
  • Enavate Sciences's Immunome position peaked at $102M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.